443INTROduCTION Endothelial dysfunction, characterized by the loss of nitric oxide bioavailability, is the key element in the pathogenesis of atherosclerosis. The significance of endothelial dysfunction has been demonstrated by numerous animal model studies 1 and has been confirmed in clinical studies showing that it precedes clinical and morphological atherosclerotic changes. 2 Numerous studies have described associations between endothelial dysfunction and risk factors for cardiovascular diseases.3-5 Impaired endothelial function is a feature of aging and is present in patients with high levels of low-density lipoproteins, arterial hypertension, diabetes, acute coronary syndromes, autoimmune diseases, and in smokers. [3][4][5][6] Moreover, the number of atherosclerotic risk factors has been linked to the degree of endothelial dysfunction.
AbsTRACTINTROduCTION Endothelial dysfunction, characterized by the loss of nitric oxide bioavailability, is a key element in the pathogenesis of atherosclerosis and an important prognostic factor in cardiovascular diseases. Therefore, the development of reliable, safe, and noninvasive methods of endothelial function assessment is important for their use in cardiovascular risk stratification. Brachial artery flow-mediated dilation (FMD) is widely used in research but technical difficulties and problems with calibration between laboratories limit its clinical use. Reactive hyperemia-peripheral artery tonometry (RH-PAT, EndoPAT) has been developed as a simpler, cheaper, and potentially more reproducible method.